The Study
The Role of GLP-1 Receptor Agonists (Ozempic and Mounjaro) as Secondary Therapy in Chronic Kidney Disease
This study is like a fair test where half the people got a new medicine and half got regular care, and then we watched what happened over three years. We saw that the people who got the medicine had better kidney and heart results—but because we don’t know if everyone was kept secret about who got what, we can’t say for sure the medicine caused it, just that it probably did.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested if a special diabetes medicine (GLP-1RA) helps people with diabetes and weak kidneys stay healthier.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 576 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — the medicine helped people keep their kidneys working longer, avoid heart attacks, lose weight, and control blood sugar better than standard treatment.
- 2People who took the medicine had 15% fewer kidney problems, 12% fewer heart attacks/strokes, dropped their blood sugar from 8.2% to 7.0%, and lost 8 kg — while those on regular care lost only 2 kg and had worse outcomes.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Revista Científica Multidisciplinar SAGA
Year
2025
Authors
Erick Adolfo Meza Soto, M. Gómez-Luján, José Eduardo Velasco Espinal, Irene Alejandra Apolo Fajardo, Humberto Mariscal, Mayra Nayeli Estrada García, Erick Trejo López, Katerin Alvarado Echeona
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.